Ki8751

Catalog No. A10502

ki8751是一种细胞可渗透的喹啉氧基苯基脲化合物，在基于细胞和无细胞的检测中起Flk-1 (VEGFR-2)选择性抑制剂的作用。

Product Citations

Kohei Ashina, .et al. VEGF-induced blood flow increase causes vascular hyper-permeability in vivo, Biochem Biophys Res Commun, 2015, Aug 21;464(2):590-5 PMID: 26163262

Technical details

Catalog Num	A10502
M. Wt	469.4
Formula	C24H18F3N3O4
Purity	>98%
Storage	at -20°C 3 years Powder
CAS No.	228559-41-9
Synonyms	Ki-8751
SMILES	COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC(=C(C=C3)NC(=O)NC4=C(C=C(C=C4)F)F)F

Biological Activity

ki8751是一种细胞可渗透的喹啉氧基苯基脲化合物，在基于细胞和无细胞的检测中起Flk-1 (VEGFR-2)选择性抑制剂的作用。

Targets

Target	Value
VEGFR2	IC50: 0.9nM
c-Kit	IC50: 40nM
PDGFRα	IC50: 67nM
FGFR2	IC50: 170nM
EGFR	IC50: >10μM
HGFR	IC50: >10μM
Insulin Receptor	IC50: >10μM

Solubility *

In vitro (25°C)	DMSO	46 mg/mL (97.99 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	4% DMSO+corn oil	2.3 mg/mL
* <1 mg/ml means slightly soluble or insoluble. * Please note that Adooq tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Preparing Stock Solutions

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
0.1 mM	21.3 mL	106.52 mL	213.04 mL
0.5 mM	4.26 mL	21.3 mL	42.61 mL
1 mM	2.13 mL	10.65 mL	21.3 mL
5 mM	0.43 mL	2.13 mL	4.26 mL

*The above data is based on the productmolecular weight 469.4. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.